The UK medicines regulator says AI will help shape how it handles evidence and regulation, with an AI Medicines Development Action Plan due next year. Its wider strategy also promises faster regulatory decisions, including halving the target for scientific advice from 90 days to 45.
Watch Desk analysis
What happened
The Medicines and Healthcare products Regulatory Agency’s Strategy 2030 sets out changes intended to support medicines and personalised treatments. Pharmaphorum reports that the strategy proposes improving how real-world evidence is generated and regulated with AI, which the MHRA describes as one of the defining medical technologies of the coming years.
The agency also plans to publish an AI Medicines Development Action Plan in 2027. Other stated targets include reducing the initial assessment time for qualifying phase 1 clinical trials to 14 days, improving data connectivity and working more closely with the health technology assessment agency NICE.
Why it matters
AI in medicines is not just a question of what a model can do. Regulators must also decide what evidence is persuasive, how it is generated and how safety is monitored. The MHRA’s strategy signals that it expects AI to affect those processes, while leaving the practical detail of the planned action plan for next year.
The timetable targets matter to medicine developers: the agency says it aims to make decisions faster and more predictable. Those are commitments in a strategy, not evidence that review times have already fallen. The real test will be whether speed and new technology improve access without leaving evidence and safety standards behind.
Our read
This is a meaningful policy direction, not a new AI approval rulebook. The useful next step is the promised action plan: it should clarify where the MHRA expects AI to change medicines development and how it will judge the resulting evidence. “AI-enabled” is a fine ambition; the details are where the regulatory work begins.
What to watch
- The AI Medicines Development Action Plan, expected next year.
- Whether the MHRA meets its 45-day scientific-advice and 14-day phase 1 assessment targets.
- How the regulator plans to assess AI-assisted real-world evidence and monitor safety.
Discussion spark: Should medicines regulators prioritise faster decisions when AI is involved, or require stronger evidence before allowing AI-assisted methods to shape approvals?
Sources and evidence
- Source update (14 October 2026, 00:00 UTC)
Watch Desk is operated by WittyWires as an independent cross-cutting AI news tracker. It does not speak for the organisations or people it covers.